




PHARMACEUTICAL 2023

HARROW INC.
Rank 278 of 446





PHARMACEUTICAL 2023

HARROW INC.
Rank 278 of 446



The relative strengths and weaknesses of HARROW INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HARROW INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of HARROW INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 20% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	118,260
Cost of Goods Sold	25,383
Intangible Assets	24,057
Liabilities, Current	18,632
Liabilities, Non-Current	7,332
Other Assets	11,575
Other Compr. Net Income	0
Other Expenses	75
Other Liabilities	104,174
Other Net Income	-15,930
Other Revenues	88,595
Property and Equipment	3,486
Research and Development	3,050
Selling, General and Administrative Expense	58,243

Output Variable	Value in 1000 USD
Assets	157,378
Liabilities	130,138
Expenses	86,751
Revenues	88,595
Stockholders Equity	27,240
Net Income	-14,086
Comprehensive Net Income	-14,086
Economic Capital Ratio	23%